These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2697592)

  • 21. Host-related immunodeficiency in the development of multiple myeloma.
    Dosani T; Mailankody S; Korde N; Manasanch E; Bhutani M; Tageja N; Roschewski M; Kwok M; Kazandjian D; Costello R; Burton D; Zhang Y; Liewehr D; Steinberg SM; Maric I; Landgren O
    Leuk Lymphoma; 2018 May; 59(5):1127-1132. PubMed ID: 28792255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired immunoresponsiveness in tumor patients.
    Harris J; Copeland D
    Ann N Y Acad Sci; 1974; 230():56-85. PubMed ID: 4595955
    [No Abstract]   [Full Text] [Related]  

  • 23. Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.
    Rasmussen T; Theilgaard-Mönch K; Hudlebusch HR; Lodahl M; Johnsen HE; Dahl IM
    Br J Haematol; 2003 Oct; 123(2):253-62. PubMed ID: 14531906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
    Kassambara A; Hose D; Moreaux J; Rème T; Torrent J; Rossi JF; Goldschmidt H; Klein B
    PLoS One; 2012; 7(7):e42161. PubMed ID: 22860071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple myeloma--recent developments in molecular and cellular biology.
    Barlogie B; Hoover R; Epstein J
    Curr Top Microbiol Immunol; 1995; 194():37-41. PubMed ID: 7895511
    [No Abstract]   [Full Text] [Related]  

  • 26. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
    Gralewski JH; Post GR; van Rhee F; Yuan Y
    Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass.
    Bianchi A; Omedé P; Attisano C; Camponi A; Dianzani U; Boccadoro M; Pileri A; Massaia M
    Haematologica; 1991; 76(5):383-8. PubMed ID: 1806441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma: why does the disease escape from plateau phase?
    Joshua DE; Brown RD; Gibson J
    Br J Haematol; 1994 Dec; 88(4):667-71. PubMed ID: 7819092
    [No Abstract]   [Full Text] [Related]  

  • 29. Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity.
    Waldmann TA; Blaese RM; Broder S; Krakauer RS
    Ann Intern Med; 1978 Feb; 88(2):226-38. PubMed ID: 305222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
    Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.
    Boccadoro M; Gavarotti P; Fossati G; Pileri A; Marmont F; Neretto G; Gallamini A; Volta C; Tribalto M; Testa MG
    Br J Haematol; 1984 Dec; 58(4):689-96. PubMed ID: 6518137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential oncogene-related gene expressions in myeloma cells resistant to prednisone and vincristine.
    Mutlu P; Ural AU; Gündüz U
    Biomed Pharmacother; 2012 Oct; 66(7):506-11. PubMed ID: 22681910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
    Yeh YA; Pappas AA; Flick JT; Butch AW
    Ann Clin Lab Sci; 2000 Jul; 30(3):283-8. PubMed ID: 10945569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The biological features of multiple myeloma.
    Michaeli J; Choy CG; Zhang X
    Cancer Invest; 1997; 15(1):76-84. PubMed ID: 9028393
    [No Abstract]   [Full Text] [Related]  

  • 35. A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy.
    Bataille R; Robillard N; Pellat-Deceunynck C; Amiot M
    Immunol Rev; 2003 Aug; 194():105-11. PubMed ID: 12846811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation.
    Templin J; Atanackovic D; Hasche D; Radhakrishnan SV; Luetkens T
    Oncotarget; 2017 Jul; 8(30):49253-49263. PubMed ID: 28512269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunology of myeloma].
    Bataille R; Klein B; Rossi JF
    Nouv Rev Fr Hematol (1978); 1987; 29(4):255-64. PubMed ID: 3320951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N- and K-ras oncogenes in plasma cell dyscrasias.
    Corradini P; Ladetto M; Inghirami G; Boccadoro M; Pileri A
    Leuk Lymphoma; 1994 Sep; 15(1-2):17-20. PubMed ID: 7858496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple myeloma: new aspects of biology and treatment.
    Ozaki S; Kosaka M
    J Med Invest; 1998 Feb; 44(3-4):127-36. PubMed ID: 9597800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.